Aisling Capital — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Urogenurogen.comin𝕏Jul 2023
UroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology.
BiotechHealthtechMedical DevicesPrinceton, US
Mark Schoenberg, M.D.(Executive Officer)Liz Barrett(President and Chief Executive Officer)inJason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Don Kim(Executive Officer)
Co-investorsMonograph Capital PartnersPontifax Venture Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.